UK 157147

Drug Profile

UK 157147

Alternative Names: UK-157,147; UK-15747

Latest Information Update: 11 Mar 2008

Price : $50

At a glance

  • Originator Pfizer
  • Class Antiasthmatics
  • Mechanism of Action Potassium channel agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Alopecia; Asthma

Most Recent Events

  • 27 Sep 2000 Pfizer has licensed the electrohydrodynamic pulmonary delivery technology of Battelle Pulmonary Therapeutics
  • 23 Jun 2000 Pfizer has merged with Warner-Lambert
  • 07 Dec 1999 Clinical trials in Asthma in United Kingdom (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top